Literature DB >> 22878939

Prevalence of type 2 diabetes in Germany in 2040: estimates from an epidemiological model.

Ralph Brinks1, Teresa Tamayo, Bernd Kowall, Wolfgang Rathmann.   

Abstract

To estimate the number of persons in the age-group 55-74 years with type 2 diabetes in Germany until 2040 and to analyze the impact of an intervention in a high risk group. A Markov model is used to generate forecasts by age and sex in each year using inputs of estimated diabetes prevalence, incidence and mortality based on actual national data. Projections about future demographics stem from the German Federal Office of Statistics. In a slightly modified model a state for persons with prediabetes is included to study the interplay of effect-size and participation quote on the number of persons with diabetes. The projected number of people with type 2 diabetes aged 55-74 years rises from 2.4 million in 2010 to 3.9 million in 2030. From 2030 on this number will decrease slightly to 3.3 million in 2040. If every second person aged 55-74 with prediabetes took part in a prevention program with the effect size of the Finnish Diabetes Prevention Program, 0.4 million cases could be prevented until 2030. To prevent 1.0 million cases in 2030, 90 % of all persons with prediabetes had to take part in an intervention that reduces the transition rate from prediabetes to diabetes by 55 %. Unless enormous efforts are spent into prevention programs, the number of persons with type 2 diabetes will increase tremendously in the next two decades.

Entities:  

Mesh:

Year:  2012        PMID: 22878939     DOI: 10.1007/s10654-012-9726-2

Source DB:  PubMed          Journal:  Eur J Epidemiol        ISSN: 0393-2990            Impact factor:   8.082


  13 in total

1.  Increasing prevalence of type 2 diabetes in a Scottish population: effect of increasing incidence or decreasing mortality?

Authors:  J M M Evans; K N Barnett; S A Ogston; A D Morris
Journal:  Diabetologia       Date:  2007-01-16       Impact factor: 10.122

2.  A dynamic Markov model for forecasting diabetes prevalence in the United States through 2050.

Authors:  Amanda A Honeycutt; James P Boyle; Kristine R Broglio; Theodore J Thompson; Thomas J Hoerger; Linda S Geiss; K M Venkat Narayan
Journal:  Health Care Manag Sci       Date:  2003-08

3.  Regional differences in the prevalence of known Type 2 diabetes mellitus in 45-74 years old individuals: results from six population-based studies in Germany (DIAB-CORE Consortium).

Authors:  S Schipf; A Werner; T Tamayo; R Holle; M Schunk; W Maier; C Meisinger; B Thorand; K Berger; G Mueller; S Moebus; B Bokhof; A Kluttig; K H Greiser; H Neuhauser; U Ellert; A Icks; W Rathmann; H Völzke
Journal:  Diabet Med       Date:  2012-07       Impact factor: 4.359

4.  Markov models in medical decision making: a practical guide.

Authors:  F A Sonnenberg; J R Beck
Journal:  Med Decis Making       Date:  1993 Oct-Dec       Impact factor: 2.583

5.  Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study.

Authors:  Jaana Lindström; Pirjo Ilanne-Parikka; Markku Peltonen; Sirkka Aunola; Johan G Eriksson; Katri Hemiö; Helena Hämäläinen; Pirjo Härkönen; Sirkka Keinänen-Kiukaanniemi; Mauri Laakso; Anne Louheranta; Marjo Mannelin; Merja Paturi; Jouko Sundvall; Timo T Valle; Matti Uusitupa; Jaakko Tuomilehto
Journal:  Lancet       Date:  2006-11-11       Impact factor: 79.321

6.  [Diabetes mellitus in the Netherlands: estimate of the current disease burden and prognosis for 2025].

Authors:  Caroline A Baan; Pieter H M van Baal; Monique A M Jacobs-van der Bruggen; Harry Verkley; Marinus J J C Poos; Rudolf T Hoogenveen; Casper G Schoemaker
Journal:  Ned Tijdschr Geneeskd       Date:  2009

7.  Projection of the year 2050 burden of diabetes in the US adult population: dynamic modeling of incidence, mortality, and prediabetes prevalence.

Authors:  James P Boyle; Theodore J Thompson; Edward W Gregg; Lawrence E Barker; David F Williamson
Journal:  Popul Health Metr       Date:  2010-10-22

Review 8.  Prediabetes: a high-risk state for diabetes development.

Authors:  Adam G Tabák; Christian Herder; Wolfgang Rathmann; Eric J Brunner; Mika Kivimäki
Journal:  Lancet       Date:  2012-06-09       Impact factor: 79.321

Review 9.  National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participants.

Authors:  Goodarz Danaei; Mariel M Finucane; Yuan Lu; Gitanjali M Singh; Melanie J Cowan; Christopher J Paciorek; John K Lin; Farshad Farzadfar; Young-Ho Khang; Gretchen A Stevens; Mayuree Rao; Mohammed K Ali; Leanne M Riley; Carolyn A Robinson; Majid Ezzati
Journal:  Lancet       Date:  2011-06-24       Impact factor: 79.321

Review 10.  Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysis.

Authors:  Clare L Gillies; Keith R Abrams; Paul C Lambert; Nicola J Cooper; Alex J Sutton; Ron T Hsu; Kamlesh Khunti
Journal:  BMJ       Date:  2007-01-19
View more
  19 in total

1.  The Rotterdam Study: 2014 objectives and design update.

Authors:  Albert Hofman; Sarwa Darwish Murad; Cornelia M van Duijn; Oscar H Franco; André Goedegebure; M Arfan Ikram; Caroline C W Klaver; Tamar E C Nijsten; Robin P Peeters; Bruno H Ch Stricker; Henning W Tiemeier; André G Uitterlinden; Meike W Vernooij
Journal:  Eur J Epidemiol       Date:  2013-11-21       Impact factor: 8.082

2.  The Generation R Study: Biobank update 2015.

Authors:  Claudia J Kruithof; Marjolein N Kooijman; Cornelia M van Duijn; Oscar H Franco; Johan C de Jongste; Caroline C W Klaver; Johan P Mackenbach; Henriëtte A Moll; Hein Raat; Edmond H H M Rings; Fernando Rivadeneira; Eric A P Steegers; Henning Tiemeier; Andre G Uitterlinden; Frank C Verhulst; Eppo B Wolvius; Albert Hofman; Vincent W V Jaddoe
Journal:  Eur J Epidemiol       Date:  2014-12-21       Impact factor: 8.082

3.  [Ophthalmological aspects of the Gutenberg Health Study (GHS): an interdisciplinary prospective population-based cohort study].

Authors:  A Mirshahi; K A Ponto; R Höhn; P S Wild; N Pfeiffer
Journal:  Ophthalmologe       Date:  2013-03       Impact factor: 1.059

4.  [Treatment of type 2 diabetes in elderly patients].

Authors:  C Girlich; U Hoffmann; C Bollheimer
Journal:  Internist (Berl)       Date:  2014-07       Impact factor: 0.743

5.  Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060.

Authors:  Bouwe P Krijthe; Anton Kunst; Emelia J Benjamin; Gregory Y H Lip; Oscar H Franco; Albert Hofman; Jacqueline C M Witteman; Bruno H Stricker; Jan Heeringa
Journal:  Eur Heart J       Date:  2013-07-30       Impact factor: 29.983

Review 6.  [Glucose metabolism in older patients].

Authors:  T Laurentius; M Freitag; J Eitner; A Eisert; T Bertsch; L C Bollheimer
Journal:  Internist (Berl)       Date:  2019-02       Impact factor: 0.743

7.  Change rates and prevalence of a dichotomous variable: simulations and applications.

Authors:  Ralph Brinks; Sandra Landwehr
Journal:  PLoS One       Date:  2015-03-06       Impact factor: 3.240

Review 8.  Nonalcoholic Fatty liver disease and risk of diabetes and cardiovascular disease: what is important for primary care physicians?

Authors:  Mohamed H Ahmed; Nazik Elmalaika Os Husain; Ahmed O Almobarak
Journal:  J Family Med Prim Care       Date:  2015 Jan-Mar

9.  Projected effect of increased active travel in German urban regions on the risk of type 2 diabetes.

Authors:  Ralph Brinks; Annika Hoyer; Oliver Kuss; Wolfgang Rathmann
Journal:  PLoS One       Date:  2015-04-07       Impact factor: 3.240

10.  Real-life effectiveness and tolerability of vildagliptin and other oral glucose-lowering therapies in patients with type 2 diabetes in Germany.

Authors:  Rüdiger Göke; Giovanni Bader; Markus Dworak
Journal:  Diabetes Ther       Date:  2014-03-19       Impact factor: 2.945

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.